ASHI Journal Club #5 - HLA‐DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Evidence for the alloimmune basis and prognostic significance of borderline T cell–mediated rejection.

Select a ModuleModule DetailsReview MaterialsEvaluate ModulePrint Certificate

Chris Wiebe, MD, FRCPC Nephrologist University of Manitoba Canadian Blood Services

Annette M. Jackson, PhD, D(ABHI) Associate Professor, Department of Surgery Chief, Clinical Transplantation Immunology Research Director, Clinical Transplantation Immunology Laboratory Duke University

September 16, 2020